<DOC>
	<DOCNO>NCT00756847</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL147 combination paclitaxel carboplatin adult solid tumor . XL147 new chemical entity inhibit PI3 Kinase . Inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell . In clinical practice , combination paclitaxel carboplatin accept treatment regimen various solid tumor , include ovarian cancer , endometrial cancer non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Safety Study XL147 ( SAR245408 ) , Combination With Paclitaxel Carboplatin Adults With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Confirmed diagnosis : Advanced solid tumor longer respond therapy OR Advanced recurrent endometrial carcinoma OR Advanced recurrent ovarian carcinoma OR Unresectable ( Stage IIIB IV ) NSCLC ECOG Performance Status 01 ( ECOG status 2 may consider follow discussion agreement sponsor ) Adequate organ bone marrow function define hematological serum chemistry limit At least 18 year old Both men woman must practice adequate contraception Informed consent Restriction therapies/medications within specific timeframes prior enrollment study include prior therapy PI3K , AKT , mTOR inhibitor , cytotoxic chemotherapy , biologic agent , nitrosoureas mitomycin C , smallmolecule kinase inhibitor , noncytotoxic hormonal agent Known allergy hypersensitivity component treatment formulation Taking oral corticosteroid chronically &gt; 1 mg/day warfarin Not recover toxic effect prior therapy History diabetes mellitus . Uncontrolled intercurrent illness Pregnant breastfeeding Congestive heart failure , unstable angina , myocardial infarction within 3 month enter study . HIV positive Diagnosis another malignancy may exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Endometrial Cancer</keyword>
</DOC>